Am Heart J:实施病例调查策略是否可提高老年人心衰和COPD的诊断率?

2020-07-31 网络 网络

心力衰竭(HF)和慢性阻塞性肺病(COPD)在老年人中往往得不到诊断,尽管这两种疾病都会抑制功能和损害健康。该研究旨在评估这些疾病的病例调查策略的有效性。

心力衰竭(HF)和慢性阻塞性肺病(COPD)在老年人中往往得不到诊断,尽管这两种疾病都会抑制功能和损害健康。该研究旨在评估这些疾病的病例调查策略的有效性。

 

这是一项集群随机试验;来自荷兰乌得勒支附近的18家普通诊所被随机分配到病例查找策略或常规护理。纳入存在呼吸困难或运动耐受性降低的多病种社区受试者(≥65岁)。病例调查策略包括病史采集、体格检查、血液检查、心电图、肺活量和超声心动图。随后的治疗决定由全科医生决定。在基线和随访6个月后,填写有关健康状况和功能的调查问卷。在6个月的随访中,我们提取了有关药物和医疗护理使用变化的信息。

 

结果,共有829名参与者被随机分配。389人在案例发现策略组,440人在常规护理组。与常规护理组相比,更多的病例寻找组患者获得了HF或COPD的新诊断(累计发生率分别为34%对2%和17%对2%)。随访6个月后,2种策略的健康状况、功能和医疗护理使用的评分相似。

 

该研究结果表明,在初级保健中对呼吸困难或运动耐受性降低的多病种老年人应用病例调查策略,提高了一些新的高频和慢性阻塞性肺病诊断,但与常规护理相比,并没有带来健康状况的短期改善。

 

原始出处:

 

Yvonne van MourikFrans H Rutten,et al., Clinical research study implementation of case-finding strategies for heart failure and chronic obstructive pulmonary disease in the elderly with reduced exercise tolerance or dyspnea: A cluster randomized trial. Am Heart J. 2020 Feb;220:73-81. doi: 10.1016/j.ahj.2019.08.021. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1981636, encodeId=d404198163678, content=<a href='/topic/show?id=87679163e47' target=_blank style='color:#2F92EE;'>#诊断率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91637, encryptionId=87679163e47, topicName=诊断率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Thu Oct 01 14:44:06 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357573, encodeId=df16135e5731d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 02 10:44:06 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563343, encodeId=a0db15633436f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Aug 02 10:44:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1981636, encodeId=d404198163678, content=<a href='/topic/show?id=87679163e47' target=_blank style='color:#2F92EE;'>#诊断率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91637, encryptionId=87679163e47, topicName=诊断率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Thu Oct 01 14:44:06 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357573, encodeId=df16135e5731d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 02 10:44:06 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563343, encodeId=a0db15633436f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Aug 02 10:44:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2020-08-02 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1981636, encodeId=d404198163678, content=<a href='/topic/show?id=87679163e47' target=_blank style='color:#2F92EE;'>#诊断率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91637, encryptionId=87679163e47, topicName=诊断率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Thu Oct 01 14:44:06 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357573, encodeId=df16135e5731d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 02 10:44:06 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563343, encodeId=a0db15633436f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Aug 02 10:44:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2020-08-02 slcumt

相关资讯

JAMA:肺气道发育水平影响老年人群COPD风险

在老年人中,气道发育不协调与COPD风险显著相关,相对于肺部,气道树径越小,COPD风险越大

NEJM:含布地奈德的三联方案可有效控制中重度COPD进展

在格隆溴铵+沙美特罗基础上,每日2次,含布地奈德的三联治疗方案可更有效的控制中重度COPD疾病进展

Respir Res:中性粒细胞弹性蛋白酶作为COPD中细菌感染的生物标记物

慢性阻塞性肺病(COPD)主要与嗜中性粒细胞炎症有关。活性中性粒细胞弹性蛋白酶(NE)是一种丝氨酸蛋白酶,由中性粒细胞分泌,以应对炎症和病原体入侵。本研究旨在探究NE是否可以作为COPD患者的细菌感染

JAMA:极早进行肺康复治疗可降低慢性阻塞性肺病恶化患者死亡风险

研究认为,对于慢性阻塞性肺病恶化患者,在出院后3个月内开始肺康复与1年死亡率的降低显著相关

Chest:血清IgG水平和COPD住院风险

低丙种球蛋白血症与较高的COPD住院风险有关。

三联疗法Breztri Aerosphere显著降低中重度COPD急性发作率

III期临床试验(ETHOS研究)表明,与双联疗法相比,阿斯利康的三联疗法Breztri Aerosphere(布地奈德/吡喃糖/富马酸福莫特罗)显著降低了慢性阻塞性肺疾病(COPD)的急性发作率。